000844796 001__ 844796
000844796 005__ 20210129233111.0
000844796 0247_ $$2doi$$a10.1007/s00259-018-3992-5
000844796 0247_ $$2ISSN$$a0340-6997
000844796 0247_ $$2ISSN$$a1432-105X
000844796 0247_ $$2ISSN$$a1619-7070
000844796 0247_ $$2ISSN$$a1619-7089
000844796 0247_ $$2pmid$$apmid:29564490
000844796 0247_ $$2WOS$$aWOS:000437733300016
000844796 0247_ $$2altmetric$$aaltmetric:34868649
000844796 037__ $$aFZJ-2018-02172
000844796 082__ $$a610
000844796 1001_ $$0P:(DE-HGF)0$$aCeccon, Garry$$b0
000844796 245__ $$aUse of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience
000844796 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2018
000844796 3367_ $$2DRIVER$$aarticle
000844796 3367_ $$2DataCite$$aOutput Types/Journal article
000844796 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1531397329_26306
000844796 3367_ $$2BibTeX$$aARTICLE
000844796 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000844796 3367_ $$00$$2EndNote$$aJournal Article
000844796 520__ $$aPurposeWe present our first clinical experience with O-(2-18F-fluoroethyl)-l-tyrosine (FET) PET in patients with high-grade glioma treated with various neurooncological therapies including tumour-treating fields (TTFields) for the differentiation of tumour progression from treatment-related changes.MethodsWe retrospectively assessed 12 patients (mean age 51 ± 12 years, range 33–72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes. Mean and maximum tumour-to-brain ratios (TBRmean, TBRmax) were calculated. The definitive diagnosis (tumour progression or posttherapeutic changes) was confirmed either by histopathology (4 of 12 patients) or on clinical follow-up.ResultsIn all nine patients with confirmed tumour progression, the corresponding FET PET showed increased uptake (TBRmax 3.5 ± 0.6, TBRmean 2.7 ± 0.7). In one of these nine patients, FET PET was consistent with treatment-related changes, whereas standard MRI showed a newly diagnosed contrast-enhancing lesion. In two patients treated solely with TTFields without any other concurrent neurooncological therapy, serial FET PET revealed a decrease in metabolic activity over a follow-up of 6 months or no FET uptake without any signs of tumour progression or residual tumour on conventional MRI.ConclusionFET PET may add valuable information in monitoring therapy in individual patients with high-grade glioma undergoing neurooncological treatment including TTFields.
000844796 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000844796 588__ $$aDataset connected to CrossRef
000844796 7001_ $$0P:(DE-HGF)0$$aLazaridis, Lazaros$$b1
000844796 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b2
000844796 7001_ $$0P:(DE-HGF)0$$aRapp, Marion$$b3
000844796 7001_ $$0P:(DE-HGF)0$$aWeber, Manuel$$b4
000844796 7001_ $$0P:(DE-HGF)0$$aBlau, Tobias$$b5
000844796 7001_ $$0P:(DE-HGF)0$$aLohmann, Phillip$$b6
000844796 7001_ $$0P:(DE-HGF)0$$aKebir, Sied$$b7
000844796 7001_ $$0P:(DE-HGF)0$$aHerrmann, Ken$$b8
000844796 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b9
000844796 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b10
000844796 7001_ $$0P:(DE-HGF)0$$aGlas, Martin$$b11
000844796 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b12$$eCorresponding author
000844796 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-018-3992-5$$n9$$p1626 - 1635$$tEuropean journal of nuclear medicine and molecular imaging$$v45$$x1619-7089$$y2018
000844796 8564_ $$uhttps://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.pdf$$yRestricted
000844796 8564_ $$uhttps://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.gif?subformat=icon$$xicon$$yRestricted
000844796 8564_ $$uhttps://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000844796 8564_ $$uhttps://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.jpg?subformat=icon-180$$xicon-180$$yRestricted
000844796 8564_ $$uhttps://juser.fz-juelich.de/record/844796/files/Ceccon2018_Article_UseOfFETPETInGlioblastomaPatie.jpg?subformat=icon-640$$xicon-640$$yRestricted
000844796 909CO $$ooai:juser.fz-juelich.de:844796$$pVDB
000844796 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b2$$kFZJ
000844796 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b9$$kFZJ
000844796 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b10$$kFZJ
000844796 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b12$$kFZJ
000844796 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000844796 9141_ $$y2018
000844796 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000844796 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000844796 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000844796 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000844796 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000844796 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000844796 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000844796 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000844796 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000844796 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000844796 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000844796 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000844796 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000844796 920__ $$lyes
000844796 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000844796 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000844796 980__ $$ajournal
000844796 980__ $$aVDB
000844796 980__ $$aI:(DE-Juel1)INM-3-20090406
000844796 980__ $$aI:(DE-Juel1)INM-4-20090406
000844796 980__ $$aUNRESTRICTED